Sagimet Biosciences Inc.
General ticker "SGMT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $214.7M (TTM average)
Sagimet Biosciences Inc. follows the US Stock Market performance with the rate: 46.2%.
Estimated limits based on current volatility of 2.6%: low 10.59$, high 11.13$
Factors to consider:
- Total employees count: 16 (+14.3%) as of 2025
- Top business risk factors: Operating losses, Inability to raise capital, Regulatory and compliance, Clinical trial delays, Manufacturing issues
- Current price 11.6% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.84$, 9.37$]
- 2026-12-31 to 2027-12-31 estimated range: [3.12$, 7.94$]
Financial Metrics affecting the SGMT estimates:
- Negative: with PPE of -3.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 2.35 > 2.08
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 95.62 > 81.92
- Negative: negative Industry operating cash flow (median)
Short-term SGMT quotes
Long-term SGMT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $32.74MM | $54.45MM | $56.89MM |
| Operating Income | $-30.74MM | $-54.45MM | $-56.89MM |
| Non-Operating Income | $2.86MM | $8.89MM | $5.85MM |
| R&D Expense | $19.78MM | $38.44MM | $39.05MM |
| Income(Loss) | $-27.88MM | $-45.57MM | $-51.04MM |
| Net Income(Loss)* | $-27.88MM | $-45.57MM | $-51.04MM |
| Stockholders Equity | $91.06MM | $155.81MM | $111.38MM |
| Assets | $96.72MM | $160.26MM | $116.48MM |
| Operating Cash Flow | $-23.77MM | $-42.44MM | $-45.65MM |
| Investing Cash Flow | $12.58MM | $-61.68MM | $4.56MM |
| Financing Cash Flow | $86.17MM | $104.82MM | $0.28MM |
| Earnings Per Share** | $-1.53 | $-1.45 | $-1.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.